ストックスクリーナーアプリを入手
2.46
2.77%
-0.07
前日終値:
$2.53
開ける：
$2.56
24時間の取引高:
38,566
Relative Volume:
0.55
時価総額：
$24.71M
収益：
$1.15M
当期純損益:
$-46.90M
株価収益率:
-0.4902
EPS:
-5.0182
ネットキャッシュフロー:
$-42.37M
1週間 パフォーマンス:
-9.23%
1か月 パフォーマンス:
-41.57%
6か月 パフォーマンス:
-72.14%
1年 パフォーマンス:
-87.23%
1日の値動き範囲:
$2.422
$2.56
1週間の範囲:
$2.385
$2.78
52週間の値動き範囲:
$2.385
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
名前
Seres Therapeutics Inc
セクター
電話
617 945 9626
住所
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
2.46 | 24.71M | 1.15M | -46.90M | -42.37M | -5.0182 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-06-23 | 開始されました | H.C. Wainwright | Buy |
| 2025-05-08 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-04-21 | 開始されました | JP Morgan | Neutral |
| 2021-07-23 | ダウングレード | Goldman | Neutral → Sell |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-03-05 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-11 | アップグレード | Jefferies | Hold → Buy |
| 2019-04-30 | 開始されました | Jefferies | Hold |
| 2018-10-22 | 開始されました | Chardan Capital Markets | Buy |
| 2017-10-13 | 開始されました | Oppenheimer | Outperform |
| 2017-08-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-02-01 | 繰り返されました | FBR & Co. | Outperform |
| 2016-08-12 | 繰り返されました | FBR Capital | Outperform |
| 2016-08-01 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-07-29 | 再開されました | H.C. Wainwright | Buy |
| 2016-03-30 | 開始されました | FBR Capital | Outperform |
| 2016-03-03 | 開始されました | Guggenheim | Buy |
| 2016-01-25 | 開始されました | H.C. Wainwright | Buy |
| 2015-10-22 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 開始されました | Canaccord Genuity | Buy |
| 2015-07-21 | 開始されました | Goldman | Neutral |
| 2015-07-21 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Seres Therapeutics Inc (MCRB) 最新ニュース
Seres Therapeutics stock at EUR 2.28, USD 25.2 million market value - ad-hoc-news.de
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 - GlobeNewswire Inc.
A liquid experimental treatment reduced two bacteria up to 1,000-fold in preclinical tests. - Stock Titan
Seres Therapeutics to Present Preclinical Data for - GlobeNewswire
Analysts see USD 17 target for Seres Therapeutics stock - AD HOC NEWS
Seres Therapeutics leaves S&P Global BMI Index. Seres Therapeutics stock gains 1.16 percent - AD HOC NEWS
Seres Therapeutics (Nasdaq:MCRB)Stock Analysis - Simply Wall Street
Seres Therapeutics, Inc.(NasdaqGS: MCRB) dropped from S&P Global BMI Index - marketscreener.com
Seres Therapeutics stock holds steady as investors await next catalysts - AD HOC NEWS
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new hires get options on 4,200 Seres shares - stocktitan.net
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences - Yahoo Finance
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - stocktitan.net
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Seres Therapeutics Inc. (MCRB) Peer Comparison – Compare with Others - Value Research
Seres Therapeutics Inc. (MCRB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Seres (MCRB) Earnings Report: The Available Earnings Metric Delivers a Beat; Post-Report: The Stock Ends Up 2.19%Profit Growth Outlook - vinanet.vn
MCRB|Seres Therapeutics Inc|Price:4.660|Chg%:+0.100 - TradingKey
Seres Therapeutics, Inc. SEC Filing (Aug 24, 2026) - Stock Titan
Seres Therapeutics reports positive SER-155 irEC study results - scanx.trade
Seres Therapeutics director Eric Shaff sells $1,196 in shares By Investing.com - Investing.com South Africa
Seres Therapeutics director Eric Shaff sells $1,196 in shares - Investing.com
Seres Therapeutics director Eric Shaff sells $1,196 in shares By Investing.com - Investing.com UK
Seres Therapeutics director Eric Shaff sells $1,196 in shares - Investing.com
Seres Therapeutics (NASDAQ: MCRB) COO sells 64 shares after 181 RSUs vest - Stock Titan
Seres Therapeutics (MCRB) director sale tied to RSU tax plan - Stock Titan
Seres Therapeutics, Inc. Revenue Breakdown – NASDAQ:MCRB - TradingView
Seres TherapeuticsMay Offer Up To $300 Million Of Securities - TradingView
Seres Therapeutics Files $300 Million Mixed Shelf - finance.yahoo.com
Seres Therapeutics Inc (MCRB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Seres Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Seres Therapeutics exits more Cambridge real estate early - The Business Journals
Seres Therapeutics Inc earnings beat by $2.77, revenue topped estimates - Investing.com
Seres Therapeutics Q2 Operating Income USD -2 - Moomoo
Seres Therapeutics, Inc. 2Q 2026: Revenue $0.736M, Net income $4.581M, EPS $0.47— 10-Q Summary - TradingView
Seres Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Seres Therapeutics (MCRB) Q2 Revenue Surpasses Expectations Amid Clinical Progress - GuruFocus
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs - The Manila Times
Seres Therapeutics Q2 Net Income Reaches $4.6 Million - Quiver Quantitative
Seres Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Seres Therapeutics reports Q2 2026 net income of $4.6M, cash $15.6M, advances SER-155 clinical plans - TradingView
MCRB: Returned to profitability in Q2 2026, driven by VOWST sale gains and SER-155 trial success - TradingView
Q2 2026 financial results released as Seres Therapeutics advances business update - Traders Union
Seres Therapeutics Reports Second Quarter 2026 Financial - GlobeNewswire
Seres Therapeutics Reports Second Quarter 2026 Financial - globenewswire.com
Seres Therapeutics: Q2 Earnings Snapshot - Yahoo Finance
Seres Therapeutics Streamlines Cambridge Operations with Lease Changes - TipRanks
Seres Therapeutics Inc (MCRB) 財務データ
収益
当期純利益
現金流量
EPS
Seres Therapeutics Inc (MCRB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Shaff Eric D. | Director |
Aug 17 '26 |
Sale |
4.55 |
263 |
1,197 |
12,499 |
| Henn Matthew R | See Remarks |
Aug 17 '26 |
Sale |
4.55 |
81 |
369 |
7,995 |
| DesRosier Thomas | See Remarks |
Aug 17 '26 |
Sale |
4.55 |
82 |
373 |
8,117 |
| TERESA L YOUNG | Officer |
May 19 '26 |
Proposed Sale |
7.69 |
167 |
1,284 |
0 |
| Shaff Eric D. | Director |
May 18 '26 |
Sale |
7.53 |
259 |
1,950 |
12,040 |
| DesRosier Thomas | See Remarks |
May 18 '26 |
Sale |
7.53 |
79 |
595 |
7,954 |
| Henn Matthew R | See Remarks |
May 18 '26 |
Sale |
7.53 |
77 |
580 |
7,838 |
| Brady Kelly | See Remarks |
May 18 '26 |
Sale |
7.53 |
59 |
444 |
8,562 |
| TERESA L YOUNG | Officer |
Mar 17 '26 |
Proposed Sale |
9.12 |
8,553 |
77,967 |
0 |
| Shaff Eric D. | Director |
Feb 15 '26 |
Sale |
8.47 |
259 |
2,194 |
11,577 |
4.22%
大文字化:
|
ボリューム (24 時間):